Solvias is a CDMO providing integrated analytical services and solutions to the biopharma and medical device industries. Its OINDP testing portfolio supports the entire development cycle for a wide range of products, such as MDIs, DPIs, nebulisers, nasal sprays and soft mist inhalers.
Solvias is a CDMO providing integrated analytical services and solutions to the pharmaceutical, biotech and medical device industries.
The Solvias OINDP analytical testing portfolio provides expert support across the entire OINDP development cycle on a wide range of products, such as pMDIs, DPIs, nebulisers, nasal sprays and soft mist inhalers. Comprehensive services offered by Solvias range from analysis of early-stage candidate formulations and device selection studies to bioequivalence and comparability studies, full-scale analytical chemistry, manufacturing and control programmes, including stability studies, and commercial batch release.
Solvias was founded in 1999 via a management buyout from Novartis, and is privately owned. The company employs almost 700 people and has multiple facilities across Europe and in the US.